New publication in JAMA Network Open - Neoadjuvant Chemoimmunotherapy in early stage NSLC - Akash Maniam, MD 🇺🇦

THE DR. A.M.G (ARUNI GHOSE) Alfredo Addeo MD

oncodaily.com/50909.html

#oncodaily #oncology #cancer #research #JAMA #lungcancer #chemoimmunotherapy #systematicreview #metaanalysis

We are happy to announce the release of our new research topic with Frontiers in Bioengineering and Biotechnology

I will be the coordinator😅

Call for papers:
#nanotechnology #Immune_Checkpoint Inhibitors
#Chemoimmunotherapy Effects #Solid_Cancers

frontiersin.org/research-topic…

New online: 'Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment' by Yangyun Wang & colleagues.

Read more👇
jnanobiotechnology.biomedcentral.com/articles/10.11…

Meta-analysis of neoadjuv chemoimmunotherapy in #NSCLC :
1. 3 cycles suffice based on pCR, with adjuvant immunotherapy not enhancing EFS.
2. Kudos to JAMA Network Open team, esp. Sara, for elevating paper quality & reviewers' feedback.
3. Special shoutout to the amazing team!

Just in The Lancet Oncology!
Role of chemoimmunotherapy in urothelial carcinoma. Should we use concurrent or sequential therapy? Pleasure to work with Sumanta K. Pal, MD, FASCO, Petros Grivas, and Luis A. Meza on this commentary!

🔗thelancet.com/journals/lanon…

Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario #lymsm Adam Suleman @ancaprica @mattcheungmd

onlinelibrary.wiley.com/doi/10.1111/bj… BSH - Haematology

Honored to have been selected to present our work on molecular biomarkers of chemoimmunotherapy response in #tnbc in the #ASCO23 #breastcancer session. #bcsm

Proud to present our pilot study where we performed early PET/CT scans on days 4 and 21 of cycle 1 of salvage chemoimmunotherapy for transplant eligible relapsed and refractory DLBCL patients @RaphaelESteiner Jason Westin, MD FACP #lymsm

tandfonline.com/eprint/6G87WN8…

Chemoimmunotherapy results “astounding” in phase II clinical trial in high-risk neuroblastoma patients, says Dr. Wayne Furman, lead researcher. Read more. ow.ly/RlIY50H4K9z Journal of Clinical Oncology

Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.

JAMA Oncology 📖 DOI 👉🏻 10.1001/jamaoncol.2024.0057

#nsclc #immunotherapy #chemoimmunotherapy #ici #lcsm

Honored to have been selected to give an oral presentation at ASCO 2023 to discuss our #breastcancer biomarker work focused on predicting response to neoadjuvant chemoimmunotherapy in #tnbc patients. University Of Kansas Radiation Oncology KU Cancer Center #bcsm

🚨Hot off the press!
It was a true pleasure working with Zeynep Zengin and oncology luminaries Sumanta K. Pal, MD, FASCO and Petros Grivas on this commentary discussing chemoimmunotherapy in UC in the light of the results of KEYNOTE-361. City of Hope Department of Medical Oncology
doi.org/10.1016/S1470-…

Bright and early at Australian and New Zealand Society for Immunology #ASI2022MEL with E. John Wherry and exhausted #Tcell s ! His papers sparked so many ideas for my #Tcell #chemoimmunotherapy #PhD !

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in #CLL : updated results of the E1912 trial ashpublications.org/blood/article/… #leusm

Very exciting work on changes in T cell function and recovery from Tcell exhaustion in NSCLC receiving immunotherapy and chemoimmunotherapy by colleague and collaborator Josh Bauml MD ⁦Joshua Bauml, MD⁩ . #wclc19 #wclc2019 #lcsm @pennradiology ⁦OncoAlert⁩

TP53 mutations in CLL: clinical impact and clonal evolution with Rx. ➡️ low VAF < 10% didn’t influence response but OS. ➡️ Chemoimmunotherapy results in clonal expansion of TP53 clone. ashpublications.org/blood/article/…

Listen to our new episode on management of newly diagnosed CLL with Nitin Jain. Dr. Jain walks us through all pivotal trials in the last decade that has transformed CLL Rx from chemoimmunotherapy to oral targeted agents!! Ashwin Kishtagari, MD #leusm #lymsm tinyurl.com/yrurztpk

Out now ACS Journal Cancer
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials acsjournals.onlinelibrary.wiley.com/doi/full/10.10…

Immunotherapy combined with tyrosine-kinase inhibitor is not better than docetaxel in NSCLS patients after first-line chemoimmunotherapy failure - Piotr Wysocki
Uniwersytet Jagielloński ASCO

#Cancer #Chemotherapy #Immunotherapy #OncoDaily #Oncology

oncodaily.com/47078.html

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells dlvr.it/SJzncC